Search results
Results from the WOW.Com Content Network
Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected.
Lilly's drug, tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management, will cease to be in shortage "very soon," CEO David Ricks said in an interview with Bloomberg in Paris.
According to the health regulator's website, 10, 12.5 and 15 milligram doses of the injection will have limited availability, while lower doses of Mounjaro were shown to be available. Eli Lilly ...
Diabetes treatment Mounjaro has been on the health regulator's shortage list since late 2022, while weight-loss drug Zepbound was added in April as demand far outstripped supply. The limited ...
A news release from Eli Lilly in June 2024 outlines some concerns surrounding compounded versions of tirzepatide (the active ingredient in Mounjaro and Zepbound), some of which contained bacteria ...
David Ricks, chair and CEO of Eli Lilly, fields a question during an announcement of the company's $3 billion expansion in Wisconsin, Thursday, Dec. 5, 2024, in Kenosha, Wis. (Sean Krajacic/The ...
Eli Lilly’s drug tirzepatide, sold under the names Mounjaro for diabetes and Zepbound for weight loss, improved symptoms in heart failure patients with obesity, the company said Thursday.
Lilly shares have rallied over 60% this year to make it the world's most valuable healthcare company by market cap as investors bet on Mounjaro's success. They were up 1.5% in choppy premarket ...